Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Randomized Studies Inappropriate For Uterine Fibroid Treatment - FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Randomized, controlled clinical trials are both impractical and ill-advised to determine the safety and efficacy of non-extirpative methods of treating uterine fibroids, FDA's Obstetrics and Gynecology Devices Panel agreed Oct. 4.

You may also be interested in...


Procedure to treat uterine fibroids uses a catheter cooled to -110degrees C prior to insertion into the fibroid for five to ten minutes, not 110degrees as was reported by "The Gray Sheet" (1Oct. 11, p. 12)

Viatris’ UpJohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign

Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts